Menopausal Hormone Replacement Therapy and Genital and Breast Cancers

A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.

A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.

Fezolinetant (Veozah) was linked to objective and patient-reported sleep gains in OPTION-VMS, with no new safety signals observed.

The prospective SOARA study will measure how often a 98%-specific ovarian cancer screening blood test leads to invasive procedures.

Wen Shen, MD, explains how clinicians can counter menopause misinformation from social media and steer patients toward evidence-based resources.

Wen Shen, MD, outlines when to treat perimenopausal symptoms and which history-taking red flags should prompt earlier bone and cardiovascular screening or referral.

Jean Cunningham, PharmD, BCPS, explains how ob-gyns can link anxiety, sleep disruption, and cognitive changes to perimenopause—and catch it earlier.

Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.